
"Value-based healthcare is about addressing the inefficiencies we see in the system. There must be incentives for professionals to seek efficiencies and act in the interest of the patients, rather than solely focusing on the treatment."
Tags:
Karin Blumer, director of global patient engagement at Swiss giant Novartis, gives fascinating insights into the global patient advocacy landscape today and how Novartis interacts with it, the work being…
Luye Pharma is a China-headquartered fully integrated oncology and CNS specialist. Bruno Delie, general manager for Switzerland, discusses the organization’s ambitious European expansion plan, looking to establish affiliates in the…
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Executive…
See our Cookie Privacy Policy Here